AAA acquires 100% share of UK nuclear medicine company

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

Advanced Accelerator Applications (AAA), a major molecular medicine company based in Bourg en Bresse, France, announced Mar. 4 that the firm had acquired 100 percent of shares of the privately held U.K.-based Imaging Equipment, a distributor of nuclear medicine technologies and radiopharmaceuticals across the U.K. and Ireland.

The agreement allows AAA full rights to Imaging Equipment’s SPECT radiopharmaceutical, IELMAG3, which is used with SPECT systems to image the urinary tract and kidneys.

The transaction also represents an opportunity for the company to break into U.K. and Irish markets, where nuclear medicine sales are comparatively strong. Imaging Equipment founders and executives now hold shares in AAA, as well. 

“The acquisition of IEL is in line with our strategy to further expand and strengthen our position in Europe,” remarked AAA chief executive officer, Stefano Buono. "The UK and Ireland are important markets for both our existing and future products. IEL's specialist expertise and strong presence in these markets is a complementary fit with AAA's business and we look forward to working with their management team to drive the integration and growth in 2014."

Imaging Equipment specializing in molecular pre-clinical and clinical imaging and is the sole distributor of AAA’s Cardiogen, a PET myocardial perfusion agent, and LuDOTATATE , an up-and-coming investigational oncology theragnostic agent. 

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.